Trial Profile
A Phase II Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Mar 2022
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Nivolumab (Primary) ; Pemetrexed (Primary) ; TG 4010 (Primary)
- Indications Adenocarcinoma; Carcinoma; Large cell carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Transgene
- 26 Mar 2022 This trial is completed in Belgium (End Date: 02 Nov 2020), according to European Clinical Trials Database record.
- 23 Nov 2020 This trial has been completed in Hungary, according to European Clinical Trials Database record.
- 16 Dec 2019 Planned End Date changed from 1 Sep 2020 to 1 Nov 2020.